Marc David Spencer, MD
Family Medicine · Englewood, CONPI 1811980733
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Gilead at 59.8% of the total. Reporting peaked in 2019 at $15,162 and has fallen 89.9% since, to $1,526 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 813 payments — averaging $41.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$20K
- AbbVie$3K
- AstraZeneca$977
- Johnson & Johnson$929
- Amgen$815
- GSK$777
- plus $7K from 54 others
What the payments were for
- Speaking & faculty fees$16,57050%
- Travel & lodging$2,4117%
- Food & beverage$14,37443%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$11,094
- Truvada$8,038
- QELBREE$478
- Inspire Upper Airway Stimulation System$124
How this compares
$33,367 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 41 | $65,643 |
| EliquisApixaban | 39 | $56,345 |
| JardianceEmpagliflozin | 50 | $45,946 |
| MounjaroTirzepatide | 39 | $40,719 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $30,212 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $22,118 |
| Bydureon BciseExenatide Microspheres | 14 | $11,627 |
| JanuviaSitagliptin Phosphate | 14 | $10,343 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,403 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,737 |
| Rosuvastatin Calcium | 344 | $3,583 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,243 |
| Gabapentin | 58 | $2,990 |
| SynthroidLevothyroxine Sodium | 25 | $1,995 |
| Omeprazole | 78 | $1,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $543 | $106,36280 claims |
| PfizerEliquis | $523 | $56,34539 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $519 | $54,34964 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $777 | $52,33060 claims |
| MerckJanuvia | $225 | $10,34314 claims |
| AbbVieSynthroid | $2,616 | $1,99525 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $80 | $1,105128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Englewood
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.